Could AI Unlock the Secrets of Life's Building Blocks?In a remarkable leap forward for biotechnology, scientists have unveiled MassiveFold, a revolutionary adaptation of Google DeepMind's AlphaFold that transforms our ability to understand protein structures. This groundbreaking system achieves what was once thought impossible: reducing protein structure prediction time from months to mere hours. By combining parallel processing with sophisticated optimization techniques, Université de Lille and Linköping University researchers have created a tool that democratizes access to one of science's most powerful capabilities.
The implications of this advancement ripple across multiple industries, from pharmaceutical development to sustainable agriculture. MassiveFold's ability to rapidly decode protein structures – the fundamental building blocks of life – accelerates our potential to develop new medicines, enhance crop yields, and create more efficient biofuels. What makes this development particularly significant is its accessibility; the system operates efficiently on both modest computing setups and advanced GPU infrastructures, making it available to research teams worldwide.
Perhaps most intriguing is MassiveFold's performance in real-world applications. During the prestigious CASP15-CAPRI blind structure prediction trials, the system demonstrated remarkable accuracy, sometimes surpassing the capabilities of its predecessor, AlphaFold3. This success, combined with its open-source availability, suggests we're entering a new era of biological understanding where the mysteries of protein structures – and thus the fundamental mechanics of life – become increasingly accessible to scientific exploration. As this technology continues to evolve, it promises to unlock new possibilities in everything from disease treatment to environmental conservation, potentially revolutionizing our approach to humanity's most pressing challenges.
Biotechnology
$AMGN observationThis is just my observation, not advice.
Technical:
1. Price touched the 200 SMA.
2. Price is corrected to 50% correction and slightly pumped after reaching the supportive zone.
3. Price reached the volume price of FRVP around 270$.
4. The correction nature of the latest candles in the blue box is obvious.
5. In the daily and 4H charts, the stock is almost in the oversold zone.
6. A significant divergence is observable on the daily chart.
Fundamental:
1. P/E ratio: 34.4x (Not undervalued)
2. In November 2024, Amgen's Phase 2 study of MariTide showed a 20% average weight loss over 52 weeks in obese patients without diabetes. While promising, it fell short of analysts' 23–25% expectations, raising concerns about its competitiveness against treatments like Eli Lilly's Zepbound and Novo Nordisk's Wegovy.
3. On November 26th, after MariTide phase 2 announcement, the price was mixed but could be considered to have moved up impulsively.
4. On 5th December, Amgen announced to invest 1B for expansion.
5. NASDAQ:AMGN launched Pavblu as a rival of NASDAQ:REGN 's Eylea.
6. On December 7th, NASDAQ:AMGN out significant result for Blinatumomab.
7. Based on reports, NASDAQ:AMGN raises quarterly dividend 5.8%.
8. Analyst sentiments: 14 buy, 15 hold, 3 sell.
Scenarios:
We are in the correction with two main scenarios:
1. ABC correction has been completed and impulsive waves have been started so we should look for entry.
2. A correction wave has been completed, and we are now in the B wave correction. In this case, we should see another price drop on wave C. After then, we can look for long on around 78% correction and trendline.
$REGN LongThis is just my observation, but not an advice.
Technical:
REGN touched its two strong trendline since 2020 and 2021.
REGN reached the 50% correction since 2020.
REGN is oversold daily and weekly.
A significant divergence is observable on daily chart.
Price touched SMA 200.
Fundamental:
P/E: 16.9x (moderate undervalue)
Since last ATH NASDAQ:REGN has come up with wide ranges of successful clinical trial outcomes. Nonetheless, prices dropped due to competitive pressures on Eylea.
Last week, after significant clinical trial results of Odronextamab and Poze-Cemdi, the market moved up. However, the price slid after the BoA's PT revision.
Analyst sentiments: 17 buy, 7 buy, 1 sell (BoA)
The long possibility is high from now on.
Can Pharma Innovation Rewrite Healthcare's Future?In the rapidly evolving landscape of medical technology, Eli Lilly emerges as a beacon of transformative potential, challenging conventional boundaries of pharmaceutical innovation. With a strategic masterstroke, the company has positioned itself at the forefront of medical breakthroughs, particularly in the revolutionary realm of weight loss and diabetes treatments. The remarkable Zepbound medication stands as a testament to this vision, demonstrating unprecedented efficacy by enabling patients to lose an average of 20.2% body weight - a figure that not only surpasses competitors but also represents a paradigm shift in medical intervention.
The company's financial architecture is equally compelling, reflecting a meticulously crafted approach to growth and shareholder value. With a staggering market capitalization of $722 billion, a 27.4% revenue growth, and an impressive 80.9% gross profit margin, Eli Lilly transcends the traditional pharmaceutical business model. Its recent $15 billion share buyback program and consistent 54-year dividend payment history underscore a strategic philosophy that balances aggressive innovation with prudent financial management, creating a blueprint for sustainable corporate success.
Beyond financial metrics and breakthrough medications, Eli Lilly represents something more profound: a vision of healthcare's future where technology, research, and human potential converge. The company's $3 billion manufacturing expansion, commitment to oncology research with drugs like Jaypirca, and continuous investment in cutting-edge medical solutions paint a picture of an organization that sees beyond immediate profit - an entity committed to reshaping human health through relentless innovation and scientific excellence. In an era of unprecedented medical challenges, Eli Lilly stands not just as a pharmaceutical company, but as a harbinger of hope, demonstrating how visionary thinking can transform global health landscapes.
ATAI Life Sciences | ATAI | Long at $1.30ATAI Life Sciences NASDAQ:ATAI , a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, is fast approaching my selected historical simple moving average (SMA). Often, but not always, the closer the price gets to this line, the higher chance there is for a fast upward move. In anticipation of this move, NASDAQ:ATAI is in a personal buy zone at $1.30.
A word of caution: this is a pure technical analysis play and this company is not expected to be profitable for many, many years...
Target #1 = $1.75
Target #2 = $2.50
Target #3 = $2.95
$VKTX is about to FEAST! Don't miss out on this BioTech trade. 🚀 Here it is: Your Free Saturday Setup! 🚀
Just as promised, here is a detailed video analysis on NASDAQ:VKTX Viking Therapeutics! 🧬 This trade meets all the criteria of my "High Five Setup" trading strategy, backed by solid technical analysis. Also, it has the potential to return over 100% on your capital deployed.
With more probabilities on our side, the likelihood of success is through the roof! 📈💥
Check it out, and let’s ride this wave together! 🌊
Stay tuned for more insights! 🔔
NFA
#Trading #StockMarket #Biotech #Investing #HighFiveSetup
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name
during the pandemic, now faces a pivotal moment.
Activist investor Starboard Value has taken a $1 billion
stake, signaling potential changes on the horizon. But
what does this mean for Pfizer's future?
The company that swiftly developed a COVID-19 vaccine
now grapples with declining sales and a tumbling
stock price. Starboard's involvement brings both challenge and
opportunity. Will this be the catalyst for Pfizer's
renaissance or a sign of deeper troubles ahead?
Former Pfizer executives have been approached to assist
in the turnaround effort. Their potential involvement adds
an intriguing layer to this unfolding story. Could
their experience and insight be the key to
unlocking Pfizer's next chapter of success and innovation?
As the pharmaceutical landscape evolves post-pandemic, Pfizer's
response to this pressure could set industry trends.
Cost-cutting, strategic refocusing and potential leadership changes loom
large. How will these moves impact drug development,
patient care, and the broader healthcare ecosystem?
For investors, patients, and industry watchers, Pfizer's
next moves are crucial. Will the company
emerge stronger, leaner, and more innovative? Or will
it struggle to find its footing in a
rapidly changing market? The answers to these questions
could reshape the future of global healthcare.
MHUA Chinese Med Tech Penny StockMHUA is shown here on the daily chart. It is currently trading at about 90% off its high of the
year. It is in the high volume area of the long term volume profile suggesting there is sufficent
liquidity to support active trading. Recent volume spikes suggest buying volume increases with
the spikes being about 10X relative volume. Price is over the POC line of the volume profile
demonstrating that buying pressure exceeds selling pressure. Price is at or near to one
standard deviation below the mean anchored VWAP and so in the undervalued area as
confirmed by the RSI Stochastic < 20 %. Chart patterns include an engulfing " big ass " candle
on 5/1 and a three-bar strike with another engulfing green candle on 5/12. Both of these
could be considered long entry signals especially when supported by the price above the POC
and the RSI. I will take a position risking 0.25% of the trading account to begin the trading
week. I am targeting a gain of $15.00 per share being a 50% retracement back to the high
YTD and a 300% return on investment. I will take a 100 share position and close 10 shares
each time the price rises by $2.00. This will adequately mitigate the risk of a volatile penny
stock while adequately rewarding the risk taken.
KRRO a biotech company with earnings coming LONGKRRO is in the biotechnology space in the gene-editing realm. It is in portfolios of C. Woods .
A recent analyst gave it an upside to 100 which is very favorable given its product line and track
record with an all-time high of about $250 ( which is about 450% over current valuation)
On the one-hour time frame, it has had a great week and is breaking out over its moving
averages as well as bullish momentum on the dual TF RSI indicator. This is a stock-long trade
in the biotechnology sector which is prognosticated to be among the best of 2024. The dramatic
reversal on the chart tells me this is a long entry. Targeting $57.5 in the short term and
$75.00 for most of the position in consideration of the analyst report.
VTYX- a risky biotechnology penny stock LONGVTRX is on a 120 minute chart, currently trading at 90% off its ATH and 50% above its absolute
long term support level. Price tried to cross above the long term mean VWAP 3 months ago
but was rejected. I anticipate that in time it will try to so so again. From 3.3 to a target of 9
would be a move in the neighborhood of 300%. I will take a small position long trade here.
This will be highly volatile. I will place a 25% stop loss to give VTRX room to roam for a couple
of earnings periods. Once the price rises 25% I will convert to a trailing stop loss of 25% and
make the then risk free trade low maintenance.
IBIO biotechnology pennystock completes retracement LONGIBIO popped 3x March 26-28 and then retraced into a standard Fib level above which it
has consolidated. The RSI lines are near to the 50 level and volumes are low. I can see where
IBIO could go higher if interest and buying volumes rise. I will watch this for the same. Having
profited heavily on the prior move, I would be happy to re-enter a long trade on IBIO.
VOR - a b iotechnology penny stock LONGVOR is a on daily chart. It is a biotechnology startup which is burning cash. As a resut this is
a speculative long trade for this company with products to treat leukemia ( blood cancer).
Price has crossed over the POC line of the volume profile and also completed an
anchored mean VWAP cross over. The Price Momentum Oscillator is reversing and buying
volume has increased since the earnings report showed less of a loss than forecasted.
I see 30% upside to the high pivot in mid-January. In conjunction with stop- loss set at the mean
anchored VWAP this is a R to r of about 3.
AVTX - a potential continuation WATCHAVTX popped on a big revenue beat on March 28th. It is now priced at about 3% of the ATH
of last July. With the massive price jump came a 15X relative volume. The question is
whether price has retraced into support and can rally again in the next market session.
This remains to be seen. i will put AVTX on the top of my watch list and take a long trade
if I see signs of continuation with volume supporting the move.
LCTX gets upgrade and is technically setup LONGLCTX on the weekly chart here has been falling since late 2021 and found support at the bottom
of the high volume area of the volume profile and ranged between it and the POC line for the
past 18 months. The is a high end clinically active biotechnology firm using stem cells to
produce therapeutic cell lines . ( One experiment using the mammary glands of cows imbedded
with cells that make insulin to make a weak milk solution containing insulin and then
concentrate it for cheap insulin is quite remarkable- ) How about some special milk for
to have with your sugar buzz) see more in the here link en.wikipedia.org
Anyway, price rose into triple confluence- the anchored mean VWAP, the POC line, the upper
boundary of the high volume area. A new analysis targets 7. Smart money is paying attention.
My smart money is paying a lot of attention. I understand the science and the market that
LCTX could reach in due time. I am not an insider but close. Enough said. My target is the
tweezer tops of 2022 at 2.5 and so 65-70% upside in the near to intermediate term and after
that maybe the analysis will revise the target up or down I am guessing the former.
VTYX- Buy the Pullback after a massive Bullish Surge LONGVTYX is an illustrative case in the trend is your friend. VTTX warmed up on Frbruary 20th and
went parabolic on the next day and then faded while the moving averages and VWAP lines
caught up. This is a buyable dip. It has now printed a couple of engulfing bullish candles. VTYX
did less than a full 0.5 retracement as a sign of strength. I will take a long trade here targeting
16% upside to the top pivot of the recent price action. If the price can reach the target I will
take half screening for higher-than-normal volatility. At present the volatility has mildly popped
over the running mean telling me the continuation is on the ready. The plus here is earnings
will report on March 24th so there is one month for traders to run the price up on this
stock in that anticipation. Options are avaiable for call contracts expiring March 15th.
JAN on watch for bullish continuation LONGJAN had earnings but I cannot find the report. It is trading with heavy volume and it shows in
the price action. Price has pulled back in the after-market in a standard Fibonacci retracement.
A pullback is appropriate here as price has gained 250% in a month. I see the pullback
as healthy and JAN is now well positioned for another bullish continuation. Volatility
and volume supports the conclusion. I will set a stop loss at 10% and targets at 50%, 75% and
100% to take partial profits on an anticipated trend up. Alerts will be set onto a set of
moving averages on the 30 minute time frame to detect death cross unders. Once profit is
hits 10% I will change the stop loss to a trailing 10% stop loss and once above 75% make the
trailing loss 5% and once over 100% change it to 3% so I can let the trade run itself from
those orders.
LVTX a possible continuation medical technology penny stock LONGLVTX is a pharmaceutical company focused on biologicals for advanced prostate carcinoma.
It recently secured a collaboration agreement with Merck to assist in the clinical trials and
the financial burdens it imposes in a quid pro quo related to a share of product margins in the
future. On the 15-minute chart, LVTX burst out of a long-standing consolidation cycle. The
majority of shareholders per Yahoo Finance are insiders and institutions primarily hedge funds.
These people are not clueless. This is a huge money inflow into the market cap. I intend
to follow the money as I see that price has retraced to a good Fibonacci level and with the
last candle may be on a reversal. I know that institutions tend to buy at the VWAP heavily
and as price is below VWAP the impetus is to buy discounted from VWAP. I will follow
the wisdom, experience and expertise of institutional traders. I will go long and assume the
risk of more of a drop with an ATR stop loss. My goal in the trade is to get a 20% gain by the
close on Monday. Getting into an insider trading move is tricky but it is interesting and
can be profitable.
VERX ATH on Earnings LONGVERX on the 15 minute chart demonstrates printing a high tight bull flag pattern in its
bullrun after the earnings report was a two line beat much like the one a quarter ago.
VERX has impressed traders including this one who got in on the ride early. I will trade
this like others recently with a similar pattern. I will hold during the consolidation and
watch for a break above the flag regression channel. I will add upon the break and
set a trailing stop loss of 5% upon a rise of another 5% keeping the profits safe while
underway. See my ideas on SOUN DUOL, VTYX and a few others. Review the link to
the pattern description here. See also my swing long trade ideas for this sector XBI and LABU.
NVAX rises impending an earnings report LONGToday NVAX is selling for a tiny fraction of its all-time high as shown in a previous idea. Earnings
is coming this upcoming week. This week NVAX news release showed it had settled a years long
litigation over a failed COVID. In the face of earnings around the corner, was this news release
a coincidence or instead a case of excellent executive and legal timing? I will skip the
conspiracy discussion.
On the chart, NVAX's bullish momentum is clear on its face. A price rise of 22% from a stock
that has been stuck in deeply undervalued territory for a significant time period is remarkable.
I have bought far out of the money call options into 2025 and 2026 some only this past month.
Those from this month are now up over 250% with 11 and 23 months to go to expiration.
I see NVAX as a risky penny medical stock with a high reward potential relative to the
risk. It is a potential buy-out candidate and bankruptcy is less likely. The rich uncle is
MRNA but the richer uncle in PFE might gain some interest. The wisest of capitalists buy out
the competition when there is an opportunity and do not worry about the government crying
monopoly when life-saving and life-extending medical products are involved. Time will tell.
I expect insane profits.
MRNA- a vaccine biotechnology stock LONGMRNA focuses on vaccine research and development and we are in the flu season an COVID is
lurking in the shadows and trying to make a comback. It had an excellent earnings report and
forward guidance. On the 60 minute chart, price has bounced up from a test of the anchored
VWAP and is at the level of the first upper VWAP while in side the high volume area of the
volume profile. The RSI is in the 60s. Bullish momentum is obvious. I will add to my ongoing
position here and again the next time I see a dip on the 15-30-minute chart. I look forward
to take a piece out of the position after the next earnings report in about 75 days. I have an
alert for relative volume when the running mean is exceeded on the 30 minute chart which
notify me to take a look at the chart. This is illustrated on this longer time frame chart about
the days around earnings but occurs from time to time from other events. As an aside, if NVAX
gets weak and develops fundamental challenges. MRNA is a potential rich uncle and could be
the leading candidate to do a takeover, friendly or otherwise.
LABU a 3X leveraged ETF of biotechnology stocks LONGLABU on a 240-minute chart has been in a trend up gaining 100% in 3 months. Both the fast and
slow ( green and red) are above the 50 level. Biotechnology is expected to be a hot subsector
this year as healthcare recovered further from the COVID pandemic anything from startups to
big pharma- from vaccines to new drugs for diabetes, liver disease and obesity. Leveraged
funds have time decay from the leveraging and management fees and are meant to be for
short-term trading. Nonetheless, 100% in 3 months is an excellent return. I add to my position
when I see a pullback on the 15-30 minute chart. If price rises more than 2% in a day I may
take 1-2 shares off the position to realize some profit and recycle ( compound) into the next
buy. According to those that follow sectors, LABU should outperform this year.